Abstract：
Bone marrow transplantation for non-malignant diseases such as aplastic anemia and hemoglobinopathies is a burgeoning clinical area. The goal of these transplants is to correct the hematopoietic defect with as little toxicity as possible. This requires mitigation of transplant-specific toxicities such as graft versus host disease, given this is not needed in non-malignant disorders. This review details current clinical outcomes in the field with a focus on post-transplantation cyclophosphamide and anti-thymoglobulin as intensive graft versus host disease prophylaxis to achieve that goal.
摘要：
用于再生障碍性贫血和血红蛋白病等非恶性疾病的骨髓移植是一个新兴的临床领域。这些移植的目的是以尽可能少的毒性纠正造血缺陷。这需要减轻移植特异性毒性，如移植物抗宿主病，鉴于这在非恶性疾病中是不需要的。这篇综述详细介绍了该领域的当前临床结果，重点是移植后环磷酰胺和抗胸腺球蛋白作为强化移植物抗宿主疾病预防以实现该目标。
